- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ASCELIA PHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging | 252 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / September 24, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced... ► Artikel lesen | |
| 10.09. | Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA | 289 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding... ► Artikel lesen | |
| 21.08. | Ascelia Pharma Q2 2026 slides: FDA meeting key after Orviglance setback | 1 | Investing.com | ||
| 20.08. | Ascelia Pharma: Focus on The Path Forward for Orviglance | 302 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / August 20, 2026 / Ascelia Pharma (STO:ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports... ► Artikel lesen | |
| 20.08. | Ascelia Pharma AB: Focus on the Path Forward for Orviglance | 223 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports - ASCELIA
KEY EVENTS IN Q2 2026Ascelia... ► Artikel lesen | |
| 17.08. | Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026 | 999 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / August 17, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that... ► Artikel lesen | |
| 15.07. | Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 511 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson... ► Artikel lesen | |
| 15.07. | Ascelia Pharma AB: Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base | 452 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In... ► Artikel lesen | |
| 12.07. | Ascelia Pharma Provides Orviglance Update | 1.029 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer... ► Artikel lesen | |
| 03.07. | Ascelia Pharma Provides Update on the Orviglance NDA | 834 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / July 3, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced... ► Artikel lesen | |
| 03.07. | Ascelia Pharma AB: Ascelia Pharma provides update on the Orviglance NDA | 866 | GlobeNewswire (Europe) | Ascelia Pharma AB (publ) (ticker: ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response... ► Artikel lesen | |
| 30.06. | Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing | 504 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 30, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing... ► Artikel lesen | |
| 09.06. | Ascelia Pharma: Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026 | 440 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / June 9, 2026 / Ascelia Pharma AB (publ)(STO:ACE) announces that Orviglance data will be presented as an oral presentation today at the European Society of Gastrointestinal... ► Artikel lesen | |
| 12.05. | Ascelia Pharma: Quarterly Report Q1 2026: Orviglance Approaching Transformative Milestones | 631 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial... ► Artikel lesen | |
| 04.05. | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 | 445 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / May 4, 2026 / Ascelia Pharma (STO:ACE) - Today, on 4 May 2026, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below.... ► Artikel lesen | |
| 30.04. | Change in Number of Shares and Votes in Ascelia Pharma AB | 388 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / April 30, 2026 / Ascelia Pharma (STO:ACE):During April, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the directed... ► Artikel lesen | |
| 09.04. | Ascelia Pharma: Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026 | 775 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / April... ► Artikel lesen | |
| 30.03. | Notice of Annual General Meeting in Ascelia Pharma AB | 411 | ACCESS Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / March... ► Artikel lesen | |
| 27.03. | Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026 | 601 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an... ► Artikel lesen | |
| 05.02. | Ascelia Pharma: Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review | 852 | ACCESS Newswire | MALMÖ, SE / ACCESS Newswire / February 5, 2026 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today published its Full Year and Q4 Report for 2025 (January - December), which is now available on the... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,775 | +0,62 % | GOLDMAN SACHS stuft NOVO NORDISK auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Novo Nordisk mit einem Kursziel von 285 dänischen Kronen auf "Neutral" belassen. Die vom Spezialisten für Diabetes-... ► Artikel lesen | |
| PFIZER | 25,210 | +0,14 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 28 US-Dollar auf "Neutral" belassen. Dies schrieb Chris Schott in seinem am Donnerstag vorliegenden... ► Artikel lesen | |
| NOVARTIS | 128,66 | +1,08 % | GOLDMAN SACHS stuft NOVARTIS AG auf 'Sell' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Novartis von 113 auf 110 Franken gesenkt und die Einstufung auf "Sell" belassen. Das aktuelle Bewertungsniveau... ► Artikel lesen | |
| MERCK & CO | 130,46 | -0,05 % | 220 Millionen US-Dollar bis 2033: Warum Moderna, Capricor und NurExone auf die richtige Wirkstoffhülle setzen | ||
| BAYER | 50,80 | +1,30 % | Aktie steigt: Bayer macht Kasse: Dieser Pharma-Deal bringt bis zu 375 Millionen Euro | © Foto: Juan Vega - EUROPA PRESSBayer verkauft Stivarga für bis zu 375 Millionen Euro an Grünenthal, stärkt damit seine Bilanz und treibt den Umbau der Pharmasparte weiter voran Enthaltene Werte: DE000BAY0017Den... ► Artikel lesen | |
| MERCK KGAA | 138,45 | +0,78 % | Bio-Techne Shareholders Approve Merck KGaA Acquisition Plan | WASHINGTON (dpa-AFX) - Wednesday, Bio-Techne Corp. (TECH) announced that its shareholders have approved the acquisition of the company by Merck KGaA (MKKGY.PK), Darmstadt, Germany, marking an... ► Artikel lesen | |
| DATAMEDS AI | 4,160 | +32,27 % | DataMEDS AI, Inc.: DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application | Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / DataMeds... ► Artikel lesen | |
| LB PHARMACEUTICALS | 37,460 | 0,00 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| SCHOTT PHARMA | 25,000 | +0,20 % | Schott Pharma: Was JPMorgans Kaufvotum jetzt auslöst | ||
| ELI LILLY | 1.048,80 | +0,94 % | So schlägt Lilly Novo | Novo stürzt an der Börse ab, trotz milliardenschwerer Wachstumspläne bis 2035. Der Grund: Ein Patent-Ablauf, der das Geschäftsmodell bedroht, und ein übermächtiger Rivale namens Eli Lilly. Die Aktien... ► Artikel lesen | |
| SANOFI | 72,29 | +0,57 % | Sanofi: Was Indiens Steuerbehörde jetzt verlangt | ||
| ETON PHARMACEUTICALS | 59,25 | +2,72 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GENERATE BIOMEDICINES | 14,910 | -1,65 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| DERMAPHARM | 39,350 | -0,64 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| ASTRAZENECA | 146,50 | +0,14 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren |
ASCELIA PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,20 % bei einem Aktienkurs von 0,049 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCELIA PHARMA AB finden Sie auf Wallstreet Online.